

---

---

**Quality of dialysis fluid for haemodialysis  
and related therapies**

*Qualité des fluides de dialyse pour hémodialyse et thérapies  
apparentées*

STANDARDSISO.COM : Click to view the full PDF of ISO 11663:2009



**PDF disclaimer**

This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat accepts no liability in this area.

Adobe is a trademark of Adobe Systems Incorporated.

Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.

STANDARDSISO.COM : Click to view the full PDF of ISO 11663:2009



**COPYRIGHT PROTECTED DOCUMENT**

© ISO 2009

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
Case postale 56 • CH-1211 Geneva 20  
Tel. + 41 22 749 01 11  
Fax + 41 22 749 09 47  
E-mail [copyright@iso.org](mailto:copyright@iso.org)  
Web [www.iso.org](http://www.iso.org)

Published in Switzerland

## Contents

Page

Foreword .....	iv
Introduction.....	v
1 Scope .....	1
2 Normative references .....	1
3 Terms and definitions .....	1
4 Requirements.....	5
4.1 Microbiological contaminants in dialysis fluid .....	5
4.2 Chemical contaminants in dialysis fluid .....	6
5 Tests for compliance with microbiological requirements.....	6
Annex A (informative) Rationale for the development and provisions of this International Standard .....	7
Annex B (informative) Reference tables from ISO 13959.....	10
Bibliography.....	13

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 11663 was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*.

STANDARDSISO.COM : Click to view the full PDF of ISO 11663:2009

## Introduction

Haemodialysis patients are directly exposed to large volumes of dialysis fluid, with the dialyser membrane being the only barrier against transfer of hazardous contaminants from the dialysis fluid to the patient. It has long been known that there could be hazardous contaminants in the water and concentrates used to prepare the dialysis fluid. To minimize this hazard, ISO 13958 and ISO 13959 set forth quality requirements for the water and concentrates used to prepare dialysis fluid. However, if the dialysis fluid is not prepared carefully, it could contain unacceptable levels of contaminants even though it is prepared from water and concentrates meeting the requirements of ISO 13958 and ISO 13959. Further, the dialysis fluid might be used as the starting material for the online preparation of fluids intended for infusion into the patient, for example, in therapies such as online haemodiafiltration. For these reasons, this International Standard for dialysis fluid quality was developed to complement the existing standards for water and concentrates, ISO 13959 and ISO 13958, respectively. Guidelines to aid the user in routinely meeting the requirements of this International Standard and ISO 13959 can be found in ISO 23500 [1].

This International Standard reflects the conscientious efforts of healthcare professionals, patients and medical device manufacturers to develop recommendations for the quality of dialysis fluid. This International Standard is directed at the healthcare professionals involved in the management of dialysis facilities and the routine care of patients treated in dialysis facilities, since they are responsible for the final preparation of dialysis fluid. The recommendations contained in this document are not intended for regulatory application.

The requirements of this International Standard aim to help protect haemodialysis patients from adverse effects arising from known chemical and microbiological contaminants that can be found in improperly prepared dialysis fluid. However, the physician in charge of dialysis has the ultimate responsibility for ensuring that the dialysis fluid is correctly formulated and meets the requirements of all applicable quality standards.

The verbal forms used in this International Standard conform to usage described in Annex H of the ISO/IEC Directives, Part 2. For the purposes of this International Standard, the auxiliary verb:

- “shall” means that compliance with a requirement or a test is mandatory for compliance with this International Standard;
- “should” means that compliance with a requirement or a test is recommended but is not mandatory for compliance with this International Standard; and
- “may” is used to describe a permissible way to achieve compliance with a requirement or test.

The concepts incorporated in this International Standard should not be considered inflexible or static. The recommendations presented here should be reviewed periodically in order to assimilate increased understanding of the role of dialysis fluid purity in patient outcomes and technological developments.

[STANDARDSISO.COM](https://standardsiso.com) : Click to view the full PDF of ISO 11663:2009

# Quality of dialysis fluid for haemodialysis and related therapies

## 1 Scope

This International Standard specifies minimum requirements for dialysis fluids used for haemodialysis and haemodiafiltration, including substitution fluid for haemodiafiltration and haemofiltration. This International Standard does not address the requirements for the water and concentrates used to prepare dialysis fluid or the equipment used in its preparation. Those areas are covered by other ISO standards.

Excluded from the scope of this International Standard are sorbent-based dialysis fluid regeneration systems that regenerate and recirculate small volumes of dialysis fluid, systems for continuous renal replacement therapy that use prepackaged solutions, and systems and solutions for peritoneal dialysis.

## 2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 13958, *Concentrates for haemodialysis and related therapies*

ISO 13959, *Water for haemodialysis and related therapies*

ISO 26722, *Water treatment equipment for haemodialysis and related therapies*

## 3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

### 3.1

#### **acid concentrate**

#### **A-concentrate**

acidified concentrated mixture of salts that, when diluted with dialysis water and bicarbonate concentrate, yields dialysis fluid for use in dialysis

NOTE 1 The term “acid” refers to the small amount of acid (usually acetic acid) that is included in the concentrate.

NOTE 2 Acid concentrate might contain glucose.

NOTE 3 Acid concentrate can be in the form of a liquid, a dry powder or a combination of the two.

### 3.2

#### **action level**

concentration of a contaminant at which steps should be taken to interrupt the trend toward higher, unacceptable levels

**3.3**  
**bicarbonate concentrate**  
**B-concentrate**

concentrated preparation of sodium bicarbonate that, when diluted with dialysis water and acid concentrate, makes dialysis fluid used for dialysis

NOTE 1 Sodium bicarbonate is also known as sodium hydrogen carbonate.

NOTE 2 Some bicarbonate concentrates also contain sodium chloride.

NOTE 3 Bicarbonate concentrate can be in the form of a liquid or a dry powder.

NOTE 4 Dry sodium bicarbonate, without added sodium chloride, is also used in concentrate generators to produce a saturated solution of sodium bicarbonate used by the dialysis machine to make dialysis fluid.

**3.4**  
**central dialysis fluid delivery system**

system that produces dialysis fluid from dialysis water and concentrate or powder at a central point and distributes the dialysis fluid from the central point to individual dialysis machines

**3.5**  
**chlorine, total**

sum of free and combined chlorine

NOTE chlorine can exist in water as dissolved molecular chlorine (free chlorine) or in chemically combined forms (combined chlorine). Where chloramine is used to disinfect water supplies, chloramine is usually the principal component of combined chlorine.

**3.6**  
**colony-forming unit**  
**CFU**

measure of bacterial or fungal cell numbers that theoretically arise from a single cell or group of cells when grown on solid media

NOTE Colonies can form from groups of organisms when they occur in aggregates.

**3.7**  
**dialysis fluid**

aqueous fluid containing electrolytes and usually buffer and glucose, which is intended to exchange solutes with blood during haemodialysis

NOTE 1 The term "dialysis fluid" is used throughout this document to mean the fluid made from dialysis water and concentrates, which is delivered to the dialyser by the dialysis fluid delivery system. Such phrases as "dialysate", "dialysis solution", or "dialysing fluid" may be used in place of dialysis fluid.

NOTE 2 The dialysis fluid entering the dialyser is referred to as "fresh dialysis fluid", while the fluid leaving the dialyser is referred to as "spent dialysis fluid".

NOTE 3 Dialysis fluid does not include prepackaged parenteral fluids used in some renal replacement therapies, such as haemodiafiltration and haemofiltration.

**3.8**  
**dialysis fluid delivery system**

device that: (1) prepares dialysis fluid on line from dialysis water and concentrates or that stores and distributes premixed dialysis fluid; (2) circulates the dialysis fluid through the dialyser; (3) monitors the dialysis fluid for temperature, conductivity (or equivalent), pressure, flow and blood leaks; (4) prevents dialysis during disinfection or cleaning modes

NOTE 1 The term includes reservoirs, conduits, proportioning devices for the dialysis fluid, and monitors and associated alarms and controls assembled as a system for the purposes listed above.

NOTE 2 The dialysis fluid delivery system can be an integral part of the single patient dialysis machine or a centralized preparation system which feeds multiple bedside monitoring systems.

NOTE 3 Dialysis fluid delivery systems are also known as proportioning systems and dialysis fluid supply systems.

### 3.9

#### disinfection

destruction of pathogenic and other kinds of microorganisms by thermal or chemical means

NOTE 1 Disinfection is a less lethal process than sterilization, because it destroys most recognized pathogenic microorganisms but does not necessarily destroy all microbial forms.

NOTE 2 This definition of “disinfection” is equivalent to low-level disinfection in the Spaulding classification.

### 3.10

#### endotoxin

major component of the outer cell wall of gram-negative bacteria

NOTE Endotoxins are lipopolysaccharides, which consist of a polysaccharide chain covalently bound to lipid A. Endotoxins can acutely activate both humoral and cellular host defences, leading to a syndrome characterized by fever, shaking, chills, hypotension, multiple organ failure and even death if allowed to enter into circulation in a sufficient dose.

### 3.11

#### endotoxin units

#### EU

units assayed by the *Limulus* amoebocyte lysate (LAL) test when testing for endotoxins

NOTE 1 Because the activity of endotoxins depends on the bacteria from which they are derived, their activity is referred to a standard endotoxin.

NOTE 2 In some countries, endotoxin concentrations are expressed in international units (IU). Since the 1983 harmonization of endotoxin assays, EU and IU are equivalent.

### 3.12

#### haemodiafiltration

form of renal replacement therapy in which waste solutes are removed from blood by a combination of diffusion and convection through a high-flux membrane

NOTE Diffusive solute removal is achieved using a dialysis fluid stream as in haemodialysis. Convective solute removal is achieved by adding ultrafiltration in excess of that needed to obtain the desired weight loss; fluid balance is maintained by infusing a replacement solution into the blood either before the dialyser (pre-dilution haemodiafiltration) or after the dialyser (post-dilution haemodiafiltration).

### 3.13

#### haemodialysis

form of renal replacement therapy in which waste solutes are removed primarily by diffusion from blood flowing on one side of a membrane into dialysis fluid flowing on the other side

NOTE Fluid removal that is sufficient to obtain the desired weight loss is achieved by establishing a hydrostatic pressure gradient across the membrane. This fluid removal provides some additional waste solute removal, particularly for higher molecular weight solutes.

### 3.14

#### haemofiltration

form of renal replacement therapy in which waste solutes are removed from blood by convection

NOTE 1 Convective transport is achieved by ultrafiltration through a high-flux membrane. Fluid balance is maintained by infusing a replacement solution into the blood either before the haemofilter (pre-dilution haemofiltration) or after the haemofilter (post-dilution haemofiltration).

NOTE 2 There is no dialysis fluid stream in haemofiltration.

**3.15**

**Limulus amoebocyte lysate test**

**LAL test**

assay used to detect endotoxin

NOTE The detection method uses the chemical response of the horseshoe crab (*Limulus polyphemus*) to endotoxin.

**3.16**

**manufacturer**

entity that designs, manufactures, fabricates, assembles, formulates or processes a finished device

NOTE Manufacturers include, but are not limited to, those who perform the functions of contract sterilization, installation, relabelling, remanufacturing, repacking or specification development, and initial distributors of foreign entities performing these functions. The term does not cover preparation of concentrates from prepackaged dry chemicals at a dialysis facility or the handling of bulk concentrates at a dialysis facility after responsibility for the concentrate is transferred from the manufacturer to the user.

**3.17**

**microbiological contamination**

contamination with any form of microorganism (e.g., bacteria, yeast, fungi and algae) or with the by-products of living or dead organisms such as endotoxins, exotoxins and cyanobacterial toxins (derived from blue-green algae)

**3.18**

**non-pyrogenic**

less than 0,03 EU/ml

NOTE Historically, the threshold pyrogenic dose of 5 EU/kg/h (the minimum dose that produces fever) has been used to set endotoxin limits of devices and injectable medications.

**3.19**

**sterile**

free from viable microorganisms with a sterility assurance level (SAL) of 6

NOTE 1 "sterile" can be used to describe a packaged solution that was prepared using a terminal sterilization process that has been demonstrated to achieve a  $10^{-6}$  microbial survivor probability, i.e., assurance of less than one chance in one million that viable microorganisms are present in the sterilized article.

NOTE 2 Alternatively, "sterile" can be used to describe a solution prepared for immediate use by a continuous process that has been validated to produce a solution free from viable microorganisms with a SAL of at least 6. This SAL applies to the total volume of solution used in a single application.

**3.20**

**substitution fluid**

fluid used in haemofiltration and haemodiafiltration treatments which is infused directly into the patient's blood as a replacement for the fluid that is removed from the blood by filtration

NOTE 1 Substitution fluid is also referred to as substitution solution or replacement solution.

NOTE 2 Substitution fluid may also be used for bolus administration, for priming of extracorporeal blood circuit and for returning blood to the patient at the end of a treatment.

**3.21**

**ultrapure dialysis fluid**

highly purified dialysis fluid that can be used in place of conventional dialysis fluid or as feed solution for possible further processing to create fluid intended for infusion directly into the blood

NOTE A widely accepted specification of ultrapure dialysis fluid is  $< 0,1$  CFU/ml and  $< 0,03$  EU/ml.

### 3.22

#### user

physician or physician's representative responsible for the actual production and handling of dialysis fluid

NOTE This medical device International Standard is mainly directed to device manufacturers, and in that context the "user" is as noted above.

## 4 Requirements

### 4.1 Microbiological contaminants in dialysis fluid

#### 4.1.1 General

The requirements contained in this clause apply to a sample of the dialysis fluid collected at the inlet to the dialyser or the reinfusion point.

#### 4.1.2 Microbiological requirements for standard dialysis fluid

Standard dialysis fluid shall contain a total viable microbial count of less than 100 CFU/ml (when tested in accordance with Clause 5) and an endotoxin concentration of less than 0,5 EU/ml (when tested in accordance with Clause 5).

NOTE 1 The action level for the total viable microbial count in dialysis fluid should be 50 CFU/ml.

NOTE 2 If microbial counts exceeding the action levels are observed in the dialysis fluid, corrective measures, such as disinfection and retesting, should be taken promptly to reduce the levels.

#### 4.1.3 Microbiological requirements for ultrapure dialysis fluid

Ultrapure dialysis fluid shall contain a total viable microbial count of less than 0,1 CFU/ml (when tested in accordance with Clause 5) and an endotoxin concentration less than 0,03 EU/ml (when tested in accordance with Clause 5). If those limits are exceeded in ultrapure dialysis fluid, corrective measures should be taken to reduce the levels to an acceptable range. The user is responsible for monitoring the dialysis fluid bacteriology of the system following installation. It is incumbent on the user to establish a regular monitoring routine.

#### 4.1.4 Microbiological requirements for online prepared substitution fluid

The requirements contained in this clause apply to online prepared fluid intended to be infused into the patient as it enters the patient's blood.

This fluid shall be sterile and non-pyrogenic.

Substitution fluid for convective therapies, such as haemodiafiltration and haemofiltration, may be produced online by a process of ultrafiltration with bacteria and endotoxin retentive filters. This online-process shall be validated to produce fluid that is sterile and non-pyrogenic.

Compliance of online produced fluid with the requirements of this International Standard cannot be demonstrated with traditional test procedures. For this reason, compliance with this International Standard shall be ensured by proper operation of a validated system, verified according to the manufacturer's instructions at the time of installation, and confirmed by the user with a regular monitoring and maintenance schedule. The user shall follow the manufacturer's instructions for use of the validated system, and the user's monitoring and maintenance schedule shall be designed to confirm that the water and concentrates used to prepare the substitution fluid continue to meet the specifications of ISO 13958 and ISO 13959.

## 4.2 Chemical contaminants in dialysis fluid

Dialysis fluid shall be prepared from water meeting the requirements of ISO 13959 and ISO 26722 and acid and bicarbonate concentrates meeting the requirements of ISO 13958. The water and concentrates shall be combined using individual dialysis fluid delivery systems or a central dialysis fluid delivery system constructed from materials that do not contribute chemical contaminants to the final dialysis fluid. The maximum levels of chemical contaminants permitted in water used to prepare dialysis fluid and concentrates are given in Tables B.1 and B.2.

## 5 Tests for compliance with microbiological requirements

Samples shall be collected where the dialysis fluid enters the dialyser.

**NOTE** In some newer dialysis machines, dialysis fluid flow stops when the effluent line is disconnected from the dialyser. In these instances, the machines are equipped with dialysis fluid sampling ports that can be accessed using a syringe. Sample ports can be disinfected with alcohol and allowed to air dry. A 30 ml sterile syringe can then be used to aspirate dialysis fluid out of and into the port before filling the syringe. The filled syringe is discarded, and a fresh sample of dialysis fluid collected using a new sterile syringe.

Samples shall be assayed within 4 h of collection, or be immediately refrigerated and assayed within 24 h of collection on a regular schedule. Total viable microbial counts (standard plate counts) shall be obtained using conventional microbiological assay procedures (pour plate, spread plate, membrane filter techniques). The calibrated loop technique shall not be used.

Preferred methods and sample volumes:

Dialysis fluid, routine test:

- spread plate, 0,1 ml – 0,3 ml;
- pour plate, 0,1 ml – 1 ml.

Ultrapure dialysis fluid, routine test:

- membrane filtration, 10 ml – 1 000 ml.

Substitution fluid:

- sterility cannot be proven by sampling.

Culture media shall be tryptone glucose extract agar (TGEA), Reasoners 2A (R2A), or equivalent. Blood agar and chocolate agar shall not be used. Incubation temperatures of 17 °C to 23 °C and an incubation time of 168 h (7 d) shall be used.

Compliance with the microbial standards for ultrapure dialysis fluid and substitution fluid prepared online with a validated system can be met by following the requirements and instructions of the manufacturer of the dialysis fluid delivery system.

The presence of pyrogens shall be determined by the *Limulus* amoebocyte lysate test for endotoxins.

## Annex A (informative)

### Rationale for the development and provisions of this International Standard

#### A.1 Microbiological contaminants in dialysis fluid

NOTE The information in this clause is intended to give the reader a historical prospective of how the microbial limits were developed for this document.

Pyrogenic reactions are caused by lipopolysaccharides or endotoxins that are associated with gram-negative bacteria. Furthermore, gram-negative water bacteria have been shown to have the capability of multiplying rapidly in a variety of hospital-associated fluids, including distilled, deionized, reverse osmosis and softened water, all of which have been used in the past as supply water for haemodialysis systems. The dialysis fluid, which is a balanced salt solution made with this water, likewise provides a very good growth medium for these types of bacterium. Several studies have demonstrated that the incidence of pyrogenic reactions can be related directly to the number of bacteria in dialysis fluid (Dawids and Vejlsgaard<sup>[10]</sup>; Favero *et al.*<sup>[14]</sup>; Favero *et al.*<sup>[15]</sup>). Even at low levels of bacterial contamination, pyrogenic reactions have been reported when the source of endotoxin was exogenous to the dialysis system (i.e. present in the community water supply) (Hindman *et al.*<sup>[18]</sup>).

Several investigators (Jones *et al.*<sup>[22]</sup>; Kidd<sup>[23]</sup>) have shown that bacteria growing in dialysis fluid can produce products that cross dialysis membranes. It has also been shown (Gazenfeldt-Gazit and Eliahou<sup>[17]</sup>; Rajj *et al.*<sup>[37]</sup>) that gram-negative bacteria growing in dialysis fluid produced endotoxins that in turn stimulated the production of anti-endotoxin antibodies in haemodialysis patients. These data suggest that bacterial endotoxins, although relatively large molecules, do indeed cross dialysis membranes, either intact or as fragments. The use of the very permeable membranes known as high-flux membranes has raised the possibility of a greater likelihood of passage of endotoxins into the blood path. Several studies support this contention. Vanholder *et al.*<sup>[51]</sup> observed an increase in plasma endotoxin concentrations during dialysis against dialysis fluid containing  $10^3$  to  $10^4$  CFU/ml *Pseudomonas* species. *In vitro* studies using both radiolabelled lipopolysaccharide and biological assays have demonstrated that biologically active substances derived from bacteria found in dialysis fluid can cross a variety of dialysis membranes (Laude-Sharp *et al.*<sup>[26]</sup>; Evans and Holmes<sup>[13]</sup>; Lonnemann *et al.*<sup>[29]</sup>; Ureña *et al.*<sup>[49]</sup>; Bommer *et al.*<sup>[9]</sup>; Schindler *et al.*<sup>[43]</sup>; Weber *et al.*<sup>[52]</sup>; Schindler *et al.*<sup>[44]</sup>). Also, patients treated with high-flux membranes are reported to have higher levels of anti-endotoxin antibodies than normal subjects or patients treated with conventional low-flux membranes (Yamagami *et al.*<sup>[53]</sup>). Finally, it was reported that the use of high-flux dialysers is a significant risk factor for pyrogenic reactions (Tokars *et al.*<sup>[46]</sup>). Although other investigators have not been able to demonstrate endotoxin transfer across dialysis membranes (Bernick *et al.*<sup>[6]</sup>; Bommer *et al.*<sup>[8]</sup>), the preponderance of reports now supports the ability of endotoxin to transfer across at least some high-flux membranes under some operating conditions. Consequently, it seems prudent to impose an upper limit on the endotoxin content of dialysis water and dialysis fluid. A level of 2 EU/ml was chosen by AAMI as the upper limit for endotoxin, since these levels were easily achieved with contemporary water treatment systems using reverse osmosis, ultrafiltration or both. At the same time the European Community chose to use 0,25 EU/ml as the maximum allowable level of endotoxin in dialysis water. When ISO 13959 was revised in 2009, the 0,25 EU/ml limit for dialysis water was included. In developing this International Standard for dialysis fluid quality, the maximum allowable level of endotoxin was set at 0,5 EU/ml by the *Limulus* amoebocyte lysate test. The level is set higher than that for dialysis water in recognition that water and concentrates can contribute endotoxin to the final dialysis fluid.

In addition to the acute risk of pyrogenic reactions, there is increasing indirect evidence that chronic exposure to low amounts of endotoxin might play a role in some of the long-term complications of haemodialysis therapy. Patients treated with ultrafiltered dialysis fluid have demonstrated a decrease in serum  $\beta_2$ -microglobulin concentrations (Quellhorst<sup>[35]</sup>; Ouseph *et al.*<sup>[33]</sup>), a decrease in markers of an inflammatory response and oxidant stress (Schindler *et al.*<sup>[42]</sup>; Sitter *et al.*<sup>[45]</sup>; Schiffel *et al.*<sup>[40]</sup>; Rahmati *et al.*<sup>[36]</sup>; Hsu *et*

*al.*<sup>[19]</sup>; Arizono *et al.*<sup>[4]</sup>; Izuhara *et al.*<sup>[20]</sup>; Furuya *et al.*<sup>[16]</sup>), and an increased responsiveness to erythropoietin (Sitter *et al.*<sup>[45]</sup>; Matsuhashi and Yoshioka<sup>[31]</sup>; Hsu *et al.*<sup>[19]</sup>; Rahmati *et al.*<sup>[36]</sup>). In longer-term studies, use of ultrafiltered dialysis fluid has been associated with a decreased incidence of  $\beta_2$ -microglobulin-associated amyloidosis (Baz *et al.*<sup>[5]</sup>; Kleophas *et al.*<sup>[25]</sup>; Schiffli *et al.*<sup>[39]</sup>), better preservation of residual renal function (McKane *et al.*<sup>[32]</sup>; Schiffli *et al.*<sup>[41]</sup>), and improved nutritional status (Schiffli *et al.*<sup>[40]</sup>, Arizono *et al.*<sup>[4]</sup>; Ouseph *et al.*<sup>[33]</sup>). These observations have led to the recommendation that dialysis fluid of a higher microbiological quality, so-called "ultrapure" dialysis fluid, should be used for routine haemodialysis (see Reference [12]). Ultrapure dialysis fluid is defined as one having a bacterial content of less than 0,1 CFU/ml and an endotoxin content of less than 0,03 EU/ml using sensitive assays (Ledebø and Nystrand<sup>[27]</sup>). This definition is now widely accepted, particularly in Europe, as the standard for dialysis fluid used to prepare substitution solution for online convective therapies. In developing this International Standard the desirability of using ultrapure dialysis fluid was recognised, but it was accepted that obtaining this level of purity on a routine basis might not yet be feasible in all dialysis settings.

Because 7 d can elapse between sampling dialysis fluid for the determination of microbiological contamination and receiving results, and because bacterial proliferation can be rapid, action levels for microbial counts were introduced into this International Standard. These action levels allow the user to initiate corrective action before levels exceed the maximum levels established by this International Standard.

In haemodialysis, the net movement of water is from the blood to the dialysis fluid, although within the dialyser there can be movement of dialysis fluid to the blood due to the phenomenon of back-filtration, particularly in dialysers with highly permeable membranes (Leypoldt *et al.*<sup>[28]</sup>). In contrast, haemofiltration and haemodiafiltration feature infusions of large volumes of electrolyte solution (20 l to more than 100 l) into the blood. Increasingly, this electrolyte solution is being prepared online from water and concentrate. The large volumes of fluid infused in haemofiltration and haemodiafiltration, and general concerns about the transfer of endotoxin and endotoxin fragments across high-flux membranes, necessitate the use of ultrapure dialysis fluid in the online preparation of substitution fluid for haemofiltration and haemodiafiltration.

## A.2 Chemical contaminants in dialysis fluid

When this International Standard was being developed, the need to include maximum levels for chemical contaminants in dialysis fluid was discussed. It was proposed that the maximum allowable levels of chemical contaminants in dialysis fluid should be the same as those in the water used to prepare the dialysis fluid since there were no data supporting the need for lower levels. Dialysis fluid is prepared from water and concentrates meeting the requirements of ISO 13959, ISO 13958 and ISO 26722, including the same requirements for maximum levels of chemical contaminants that were proposed for inclusion in this International Standard. Because the water and concentrates are combined using individual dialysis machines or central dialysis fluid delivery systems that are required to be constructed of materials that do not contribute chemical contaminants to the dialysis fluid, it was concluded that including maximum allowable levels of chemical contaminants in the dialysis fluid would be redundant and impose an unnecessary burden on dialysis facilities.

## A.3 Tests for compliance with microbiological requirements

The original clinical observations showing a relationship between bacterial levels in dialysis fluid and pyrogenic reactions were based on cultures performed with standard methods agar (SMA), a medium containing relatively few nutrients, (Favero *et al.*<sup>[14]</sup>). Later, the use of tryptic soy agar (TSA), a general-purpose medium for isolating and cultivating fastidious organisms, was recommended because it was thought more appropriate for culturing bicarbonate-containing dialysis fluid. However, several studies have shown that the use of tryptone glucose extract agar (TGEA) or R2A results in an increased recovery of bacteria from water and dialysis fluid (Ledebø and Nystrand<sup>[27]</sup>; van der Linde *et al.*<sup>[50]</sup>; Pass *et al.*<sup>[34]</sup>; Reasoner and Geldreich<sup>[38]</sup>). Extending the culturing time up to 168 h and using a lower incubation temperature have also been shown to increase the recovery of bacteria compared to incubation for 48 h at 35 °C as recommended in ANSI/AAMI RD52<sup>[2]</sup> (Ledebø and Nystrand<sup>[27]</sup>; Pass *et al.*<sup>[34]</sup>; Reasoner and Geldreich<sup>[38]</sup>). The membrane filtration technique is applied when higher sensitivity is required or desired. The use of larger volumes (up to 1 000 ml) will provide greater sensitivity, but the improved sensitivity needs to be balanced against the increased risk of contamination in collecting and handling the sample. Even with the most sensitive techniques,

compliance with the stringent requirements for online prepared substitution fluid cannot be demonstrated by culturing; it has to be assured by use of a validated process.

The culturing conditions recommended in this International Standard could fail to identify the presence of some organisms. Specifically, the recommended method might not detect the presence of various non-tuberculous mycobacteria that have been associated with several outbreaks of infection in dialysis units (Bolan et al.<sup>[7]</sup>; Lowry et al.<sup>[30]</sup>), or fungi and yeast, which have been shown to contaminate dialysis fluid (Klein et al.<sup>[24]</sup>).

STANDARDSISO.COM : Click to view the full PDF of ISO 11663:2009

## Annex B (informative)

### Reference tables from ISO 13959

**Table B.1 — Maximum allowable levels of toxic chemicals and dialysis fluid electrolytes in dialysis water<sup>a</sup>**

Contaminant	Maximum concentration (mg/l) <sup>b</sup>
<b>Contaminants with documented toxicity in haemodialysis</b>	
Aluminium	0,01
Total chlorine	0,1
Copper	0,1
Fluoride	0,2
Lead	0,005
Nitrate (as N)	2
Sulfate	100
Zinc	0,1
<b>Electrolytes normally included in dialysis fluid</b>	
Calcium	2 (0,05 mmol/l)
Magnesium	4 (0,15 mmol/l)
Potassium	8 (0,2 mmol/l)
Sodium	70 (3,0 mmol/l)
NOTE This table is reproduced from ISO 13959.	
<sup>a</sup> The physician has the ultimate responsibility for ensuring the quality of water used for dialysis.	
<sup>b</sup> Unless otherwise noted.	

**Table B.2 — Maximum allowable levels of trace elements in dialysis water**

Contaminant	Maximum concentration (mg/l)
Antimony	0,006
Arsenic	0,005
Barium	0,1
Beryllium	0,0004
Cadmium	0,001
Chromium	0,014
Mercury	0,0002
Selenium	0,09
Silver	0,005
Thallium	0,002
NOTE This table is reproduced from ISO 13959.	

Chemical analyses of the substances listed in Tables B.1 and B.2 can be obtained by using methods referenced by the American Public Health Association [3], methods referenced by the U.S. Environmental Protection Agency [47], and/or other equivalent analytical methods. Where testing for the individual trace elements listed in Table B.2 is not available, an analysis for total heavy metals can be used with a maximum allowable level of at 0,1 mg/l.

**Table B.3 — Analytical tests for chemical contaminants**

Contaminant	Test name	Reference, test number
Aluminium	Atomic Absorption (electrothermal)	American Public Health Assn, #3113
Antimony	Atomic Absorption (platform)	US EPA, #200.9
Arsenic	Atomic Absorption (gaseous hydride)	American Public Health Assn, #3114
Barium	Atomic Absorption (electrothermal)	American Public Health Assn, #3113
Beryllium	Atomic Absorption (platform)	US EPA, #200.9
Cadmium	Atomic Absorption (electrothermal)	American Public Health Assn, #3113
Calcium	EDTA Titrimetric Method, or Atomic Absorption (direct aspiration), or Ion Specific Electrode, or Inductively-coupled plasma spectrometry (direct aspiration)	American Public Health Assn, #3500-Ca D American Public Health Assn, #3111B
Total chlorine	DPD Ferrous Titrimetric Method, or DPD Colorimetric Method	American Public Health Assn, #4500-Cl F American Public Health Assn, #4500-Cl G
Chromium	Atomic Absorption (electrothermal)	American Public Health Assn, #3113
Copper	Atomic Absorption (direct aspiration), or Neocuproine Method	American Public Health Assn, #3111 American Public Health Assn, #3500-Cu D
Fluoride	Ion Selective Electrode Method, or SPADNS Method	American Public Health Assn, #4500-F <sup>-</sup> C American Public Health Assn, #4500-F <sup>-</sup> D
Lead	Atomic Absorption (electrothermal)	American Public Health Assn, #3113
Magnesium	Atomic Absorption (direct aspiration), or Inductively-coupled plasma spectrometry (direct aspiration)	American Public Health Assn, #3111
Mercury	Flameless Cold Vapor Technique (Atomic Absorption)	American Public Health Assn, #3112
Nitrate	Cadmium Reduction Method	American Public Health Assn, #4500-NO <sub>3</sub> E
Potassium	Atomic Absorption (direct aspiration), or Flame Photometric Method, or Ion Specific Electrode, or Inductively-coupled plasma spectrometry (direct aspiration)	American Public Health Assn, #3111 American Public Health Assn, #3500-K D American Public Health Assn, #3500-K E
Selenium	Atomic Absorption (gaseous hydride), or Atomic Absorption (electrothermal)	American Public Health Assn, #3114 American Public Health Assn, #3113
Silver	Atomic Absorption (electrothermal)	American Public Health Assn, #3113